Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,912
  • Shares Outstanding, K 56,867
  • Annual Sales, $ 6,000 K
  • Annual Income, $ -41,830 K
  • 36-Month Beta 2.17
  • Price/Sales 3.40
  • Price/Cash Flow N/A
  • Price/Book 1.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.18
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.20 +41.67%
on 01/30/19
1.73 -1.73%
on 02/21/19
+0.46 (+37.10%)
since 01/18/19
3-Month
1.00 +70.00%
on 12/26/18
1.73 -1.73%
on 02/21/19
+0.31 (+22.30%)
since 11/21/18
52-Week
1.00 +70.00%
on 12/26/18
2.92 -41.78%
on 10/02/18
-0.14 (-7.61%)
since 02/21/18

Most Recent Stories

More News
Analysis: Positioning to Benefit within Conagra Brands, National Retail Properties, PRA Health Sciences, Westinghouse Air Brake Technologies, YRC Worldwide, and Infinity Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG),...

YRCW : 8.18 (-0.24%)
CAG : 24.07 (+0.17%)
WAB : 73.58 (-2.00%)
INFI : 1.70 (+24.09%)
PRAH : 111.99 (-1.68%)
NNN : 52.54 (+1.94%)
Infinity Pharmaceuticals To Present At BIO CEO & Investor Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February...

INFI : 1.70 (+24.09%)
Infinity Pharmaceuticals Provides 2019 Goals and Financial Guidance

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced anticipated 2019 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting tumor-associated myeloid cells...

JPM : 105.47 (-0.21%)
INFI : 1.70 (+24.09%)
Infinity To Present At 37th Annual J.P. Morgan Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019, at 9:30 a.m. PST (12:30 p.m. EST) in San Francisco,...

JPM : 105.47 (-0.21%)
INFI : 1.70 (+24.09%)
Infinity (INFI) Down 48.3% Since Last Earnings Report: Can It Rebound?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.70 (+24.09%)
Today's Research Reports on Stocks to Watch: Infinity Pharmaceuticals and athenahealth

NEW YORK, NY / ACCESSWIRE / November 13, 2018 / Despite promising data released over the weekend, Infinity Pharmaceuticals tanked on Monday with a loss of over 45%. Shares of athenahealth Inc. were in...

INFI : 1.70 (+24.09%)
Detailed Research: Economic Perspectives on MetLife, Callon Petroleum, Five9, Ballard Power, Infinity Pharmaceuticals, and Commercial Vehicle Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MetLife, Inc. (NYSE:MET),...

CPE : 7.14 (-4.80%)
BLDP : 3.56 (-5.07%)
INFI : 1.70 (+24.09%)
CVGI : 8.22 (+1.73%)
FIVN : 52.28 (+1.57%)
MET : 44.76 (-0.64%)
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer

Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer

CGEN : 3.52 (unch)
JNJ : 135.42 (-0.68%)
INFI : 1.70 (+24.09%)
BMY : 50.13 (-2.28%)
Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y

Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of...

RCUS : 11.99 (+3.36%)
INFI : 1.70 (+24.09%)
VSTM : 3.18 (+1.60%)
BMY : 50.13 (-2.28%)
Infinity: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Monday reported third-quarter net income of $13.4 million, after reporting a loss in the same period a year earlier.

INFI : 1.70 (+24.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade INFI with:

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 2.01
1st Resistance Point 1.85
Last Price 1.70
1st Support Level 1.42
2nd Support Level 1.15

See More

52-Week High 2.92
Fibonacci 61.8% 2.19
Fibonacci 50% 1.96
Fibonacci 38.2% 1.73
Last Price 1.70
52-Week Low 1.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar